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Summary 
Natural autoantibodies are primarily immunoglobuhn M (IgM) antibodies that bind to a variety 
of self-antigens, including self-IgG. Accounting for a large proportion of the early B cell repertoire, 
such polyspecific autoantibodies are speculated to contribute to the homeostasis and/or competence 
of the primary humoral immune system. Recent studies indicate that the leukemia cells from 
most patients with chronic lymphocytic leukemia (CLL) also express uch IgM autoantibodies. 
Similarly, the leukemia cells from many CLL patients react with murine monoclonal ntibodies 
(mAbs) specific for crossreactive idiotypes (CtLIs) associated with human IgM autoantibodies. 
In particular, leukemic ells frequently react with G6, a mAb specific for an Ig heavy chain (H 
chain)-associated CRI, and/or with 17.109, amAb that defines aK light chain (L chain)-associated 
CRI. Generated against IgM rheumatoid factor (RF) paraproteins, G6 and 17.109 each recognize 
a major CRI that is present in many IgM RF paraproteins. Furthermore, over 90% of the IgM 
paraproteins found to bear both H and L chain-associated CtLls also are found to have tLF activity. 
Molecular characterization of these CILIs demonstrates hat each is a serologic marker for expression 
of a highly conserved Ig V gene. As such, the frequent production of IgM polyspecific autoantibodies 
in CLL simply may reflect he frequent use of such highly conserved autoantibody-encoding 
Ig V genes with little or no somatic mutation. To test this hypothesis, we generated murine 
transfectomas to pair the 17.109-reactive K L chain of SMI, a 17.109/G6-reactive CLL population, 
with the Ig H chain of SMI or other G6-reactive leukemia cells or tonsillar lymphocytes. 
Cotransfection fvectors encoding the Ig H and L chains of SMI generated transfectomas that 
produce IgM~ RF autoantibodies reactive with human IgG1 and IgG4. In contrast to 
G6/17.109-reactive IgM~ ILF Waldenstrom's paraproteins, the SMI IgM~ also reacts with several 
other self-antigens, including myoglobin, actin, and ssDNA. However, cotransfection f the SMI 
L chain with a vector encoding any one of 10 different G6-reactive Ig H chains generated 
transfectomas that produce IgM~ antibodies without detectable polyspecific autoantibody 
activity. These results indicate that polyspecific antiself-reactivity of G6/17.019-reactive Ig is 
dependent on the somatically generated Ig third complementarity determining region. Collectively, 
these studies imply that selection may be responsible for the frequent expression of polyspecific 
autoantibodies in CLL and early B cell ontogeny. 
r '~he  leukemia cells from many patients with chronic lym- 
1 .IL phocytic leukemia (CLL) produce polyspecific IgM au- 
toantibodies. Early studies by Prend'homme and Seligmann 
(1) indicated that CLL patients have leukemia cells that fre- 
quently bear surface membrane IgM that has RF activity, 
or binding activity for human IgG. In another limited survey, 
four of thirteen CLL patients were found to have leukemia 
cells that expressed surface IgM (slgM) with binding activity 
I Abbreviations u ed in this ~per: BBS, borate buffered saline; CLL, chronic 
lymphocytic leukemia; CKI, crossreactive idiotypes. 
for human IgG (2). Subsequent s udies demonstrated that 
over half of all CLL patients have leukemia cells that can be 
stimulated to secrete autoantibodies in vitro that bind to a 
variety of self-antigens, most notably human IgG (3-6). Al- 
though each of the leukemia cell cultures in these studies was 
monoclonal, the secreted autoantibodies generally were poly- 
specific, each Ig binding to two or more distinct self-antigens, 
e.g., human IgG, ssDNA, dsDNA, histones, cardiolipin, actin, 
thyroglobulin, and/or cytoskeletal components. Collectively, 
these studies indicate that the leukemia cells from most CLL 
patients may express polyreactive autoantibodies. 
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Similarly, the leukemia cells of many CLL patients react 
with mAbs specific for crossreactive idiotypes (CRIs) of IgM 
autoantibodies. Approximately one-fifth of the patients with 
K L chain-expressing CLL, for example, were found to have 
leukemia cells that express aK L chain-associated CRI defined 
by a mAb, designated 17.109 (7, 8). Furthermore, a high 
proportion of CLL patients have leukemia cells that react with 
G6 (8, 9), a mAb specific for an Ig H chain-associated CRI. 
Generated against monoclonal IgM RF paraproteins, both 
17.109 and G6 recognize CRIs present on many IgM au- 
toantibodies, particularly RFs (10-12). In addition, over 90% 
of the monodonal IgM paraproteins that have both H and 
L chain CRIs are noted to have RF activity (13). 
Evaluation of the molecular basis for expression of these 
CRI reveals that each is a serologic marker for a conserved 
Ig V gene expressed with little or no somatic mutation (14, 
15). For example, the 17.109-reactive (17.109 +) neoplastic B
cells from unrelated patients express nearly identical V~ 
genes that share more than 99% nucleic acid sequence ho- 
mology with a germline V~III gene isolated from placental 
DNA, designated Humkv325 (14-16). Similarly, G6-reactive 
(G6 +) leukemia cells from unrelated patients, as well as G6 + 
tonsillar lymphocytes from healthy donors (17), express ho- 
mologous V, genes of the V.1 subgroup, designated 51pl 
(18, 19). Conceivably, the frequent expression of IgM au- 
toantibodies in CLL may be a direct consequence of the 
repeated use of such highly-conserved Ig V genes. This model 
is supported by the work of Sanz et al. (20), suggesting that 
natural polyreactive autoantibodies are encoded by a restricted 
repertoire of nonmutated Ig V genes. 
However, this model minimizes the contribution of the 
third CDR (CDR3) to the autoreactive binding activity of 
the Ig expressed in CLL. This region of the Ig H chain is 
encoded by the D and J, gene segments, that undergo re- 
combination and NH2-terminal nucleic acid base insertion 
immediately prior to V. gene rearrangement (21, 22). Ac- 
cordingly, the sequence of the CDR3 generally is idiosyn- 
cratic to each Ig V. gene rearrangement, ashas been noted 
with all G6 + H chains sequenced to date (17, 18, and un- 
published observations). In view of the large potential for 
diversity in the CDR3 of G6 + H chains (17), the random 
pairing of a 17.109 + K L chain with any G6 + Ig H chain 
may not be anticipated to form an autoantibody if the CDR3 
is critical to autoantibody binding activity. 
To examine this, we generated murine transfectomas to pair 
the 17.109 + g L chains of SMI, a 17.109/G6 +CLL B cell 
population, with each of several different G6 + H chains ex- 
pressed by normal or leukemic B cells. We find that the my- 
eloma cells cotransfected with the original pair of Ig H and 
L chain genes of SMI secrete polyreactive IgM, RF autoan- 
tibodies. However, myeloma cells co-transfected with the SMI 
L chain gene and any one of ten different G6 H chain genes 
produced IgM~ that failed to have such polyspecific autoreac- 
tivity. Collectively, this study indicates that the polyspecific 
autoreactivity of the "natural" autoantibodies frequently noted 
in CLL and early B cell ontogeny is a selected specificity. 
Materials and Methods 
Antibodies. Purified polyclonal human IgG was obtained from 
Cappel Research Products (Durham, NC). We obtained purified 
myeloma proteins of each IgG isotype from Dr. Hans Spiegelberg 
(University of California, San Diego, School of Medicine, La Jolla, 
CA). Another set of purified mydoma proteins of each IgG iso- 
type was purchased from Calbiochem Corp. (San Diego, CA). G6, 
a murine IgG1 mAb reactive with an autoantibody H chain- 
associated CRI (12) was obtained from Drs. Rizgar Mageed and 
Roy Jefferis (University of Birmingham, Birmingham, England). 
DA4-4, an IgG1 anti-human #H chain-producing hybridoma (23), 
was obtained from the American Type Tissue Culture Collection 
(Rockvilh, MD). Anti-human g or anti-human XmAb-producing 
hybridomas were as described (7, 14). The IgM~ R.F paraprotein 
BOLL, isolated from the plasma of a patient with mixed cryoglob- 
ulinemia, was donated by Dr. R. Wistar, Jr. (National Naval Med- 
ical Center, Bethesda, MD). The IgM Waldenstrom's paraprotein, 
ME591, is as described (24). MOPC-21, an IgGl~ mouse myeloma 
protein of unknown specificity, was produced by P3X63Ag8 (25). 
This cell line was obtained from the American Type Culture Col- 
lection. Antibodies were precipitated from ascites or culture super- 
natants in 50% ammonium sulfate. After at least I h at 4~ the 
samples were spun for 10 min at 10,000 g. The harvested Igprecipi- 
tate was suspended and dialyzed extensively in PBS, pH 7.2. Column 
chromatography of transfectoma Ig was performed with Superose- 
6 TM in PBS at 4~ using an FPLC apparatus (Pharmacia, Uppsala, 
Sweden). 
Vector Constructions. We isolated the rearranged gene complexes 
encoding the K L chain and the # H chain of G6-CRI+/17.109 - 
CRI + leukemic ells of CLL patient, SMI. For this we partially 
digested SMI genomic DNA with Sau3a. Large sized fragments 
were isolated on sucrose density gradients for ligation into X dash TM 
with BamHI compatible overhangs (Stratagene Inc., La Jolla, CA), 
as described (26). For the ~ L chain, a 17.8-kb BamHI fragment 
was isolated that contained the ~ L chain promoter, earranged V,
gene, L chain enhancer and ~ L chain constant region exon. This 
fragment was ligated in pSV2-gpt, a SV40 DNA plasmid vector 
with the Escherichia coli gpt gene (Ecogpt), encoding xanthine- 
guanine phosphoribosyltransferase (27). Expression of this gene 
allows for selection of transfected mammalian cells with myco- 
phenolic acid (27, 28), as described (29) (see Fig. 1 A). In addition, 
a recombinant clone was isolated from the SMI genomic library 
that contained the rearranged H chain of SMI. An EcoRI/HindIII 
digest of this recombinant insert yielded a 3.4-kb fragment hat 
contained the Ig promoter, the functionally rearranged V. gene 
and the H chain enhancer region. This fragment was subcloned 
into Bluescript TM (Stratagene Inc.). 
Unique restriction sites were introduced at sites flanking the 
H chain variable region gene to allow for the removal and subse- 
quent insertion of different rearranged V, genes isolated via PCR. 
For this, ssDNA was synthesized using the R408 helper phage 
(Stratagene Corp.). Unique restriction enzyme sites then were in- 
troduced via site-directed mutagenesis u ing synthetic oligonucle- 
otides and the Oligonucleotide-Directed-Mutagenesis-System TM 
version 2 (Amersham Corp., Arlington Heights, IL). A ClaI site 
was introduced 5' of the leader sequence and a SalI site was intro- 
duced 3' of the J, segment. Mutants initially were screened by 
digestion of plasmids prepared from independent colonies and 
checked by dsDNA sequencing using oligonucleotide complemen- 
tary to sequences 100-bp contiguous to the introduced site, as de- 
scribed (14). 
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This modified 3.4-kb rearranged V. gene fragment was ligated 
onto an 7.4-kb BamHI-HindlII fragment containing the human 
/z constant region exons excised from pN. x-/zTNP (30), that orig- 
inally was derived from the cloned segment ~, C75 (31. This frag- 
ment, in turn, was ligated onto an EcoRI/BamHI fragment of 
pN. x-#TNP (30), containing the E. coli neo rgene, the SV40 ori, 
pBR322 ori, and ampicillin resistance gene to create pRTM1 (see 
Fig. 1 B). The plasmid pN. x-/~TNP originally was obtained from 
Dr. M.J. Shulman (University of Toronto, Toronto, Canada) (30). 
Synthetic Oligonucleotides. PCR primers, site-directed mutagen- 
esis oligonucleotides and probes were synthesized on a Pharmacia 
Gene Assembler (Pharmacia). Probes were 5' end-labeled with 
3,-[3zP]ATP and polynucleotide kinase, as described (7). 
Cloning Rearranged G6-encoding V. Genes Into pRTM1. Rear- 
ranged G6-encoding V.1 genes isolated from normal tonsillar (17) 
or neoplastic B cells (18) were cloned and sequenced in Bluescript TM 
(Stratagene Inc.) as described (15, 17, 18). The rearranged V.I 
genes of SIC, HEN, BRA, and HUR were cloned from the genomic 
DNA isolated from CD5 B call lymphoma tissues of patients with 
G6-reactive CLL (8). SMI, AND, and NEI were isolated from G6- 
reactive leukemia cells (18). To clone each rearranged V.1 gene 
into pRTM1, we performed PCR on each recombinant plasmid 
using oligonucleotides specific for the V.1 leader sequence (dGCA 
TCG ATA ATC ACC ATG GAC), or to a J. consensus equence 
(dGCG TCG ACT CTG AGG AGA CGG TGA) that have the 
flanking restriction enzyme sites ClaI or SalI, respectively. This 
generated PCR products of'v660 bp that were digested with ClaI 
and Sail, to yield VHl-containing inserts that were purified via 
agarose gel electrophoresis. These inserts were ligated into pRTM1 
that had been digested with SalI and ClaI and then isolated free 
of the SMI V.1 insert via 0.8% agarose gel electrophoresis. The 
ligated plasmids each were used to transform XL1Blue TM (Stratagene, 
Inc.). Ampicillin-resistant transformants were screened via blot hy- 
bridization with a radiolabeled oligonucleotide (dGCG TAG TTT 
GCT GTA CC) specific for a sequence within the CDR2 of the 
V.1 gene(s) encoding the G6-CRI, as described (18, 32). 
Transfectomas. P3X63-AgS.653, anonsecreting mouse myeloma 
cell line (33), was obtained from the American Type Culture Col- 
lection. These cells were cultured in RPMI-1640 (Whittaker 
Bioproducts, Walkersville, MD) containing 20% FCS (HyClone 
Laboratories, Inc., Logan, UT) and 2-mM r-glutamine (Mediatech 
Inc., Washington, DC). Cells were washed and then suspended 
in ice cold RPMI at 1.5 x 107/ml. One ml of the cell suspension 
was then mixed with 2-mg linearized vector DNA and then trans- 
ferred into a cold plastic cuvette containing two aluminum elec- 
trodes (Bio-Rad Laboratories, Richmond, CA). An electric pulse 
of 1,000 V/cm with a capacitance of 960 mF was applied to the 
solution using a Gene-Pulser TM apparatus (Bio-Rad Laboratories), 
as described (34). After the electric pulse, the cells were kept on 
ice for 10 min and then transferred to a flask of warm culture 
medium. 2 d after the electroporation, the medium was adjusted 
to I mg/ml of G418 (Geneticin; Gibco Bethesda Research Labora- 
tories, Gaithersburg, MD) and/or 250 mg/ml xanthine (Sigma 
Chemical Co., St. Louis, MO), 15 mg/ml hypoxanthine (Sigma 
Chemical Co.), and I mg/ml mycophenolic a id (Sigma Chemical 
Co.), respectively, toselect for transfectomas expressing E. coli neo r
and/or gpt genes of the transfected plasmids. 
ELISA. To measure the concentrations of IgM, IgM,, or 
CRI-bearing Ig, polystyrene microtiter plates were incubated with 
murine mAbs HB-57 (anti-human IgM), 17.109, or G6, at 5-10 
#g/ml of borate buffered saline (BBS, pH 8.2). After incubation 
for over 1 h, plates were washed and then exposed to 1% bovine 
gelatin (J. T. Baker Inc., Phillipsburg, NJ) in BBS for 1 h at room 
temperature to block residual protein binding sites. Culture super- 
natants, concentrated transfectoma Ig, or purified IgM~ para- 
protein were titrated in 1% gelatin in BBS and then added to the 
washed plates for a 1 h incubation at room temperature. Plates were 
then washed with 0.05% Tween in BBS before addition of alkaline 
phosphatase-conjugated goatantibodies specific for the human Ig 
/z chain or ~ L chain (Southern Biotech., Birmingham, AL) to assay 
for IgM or IgM~, respectively. After another 1-h incubation at 
room temperature, plates were washed and then developed with 
aminoethylcarbozole in carbonate buffer (pH 9.8). The optical den- 
sity at 405 nm of each of the wells was accessed using a Ther- 
moMax TM (Molecular Devices Corp., Menlo Park, CA) ELISA plate 
reader linked to a Macintosh pl~s (Apple Computer, Cupertino, CA) 
computer for protein concentration a alyses using A SOFT TM soft- 
ware (BioMetallic Inc., Princeton, NJ). For standards we used the 
IgM, RF paraprotein, BOIL, and an IgM~ Waldenstrom's 
paraprotein, ME591, of irrelevant specificity. Binding to other self- 
antigens was measured similarly, except that the polystyrene plates 
were coated with bovine actin, bovine thyroglobulin, purified sin- 
glestranded calf thymus DNA (Sigma Chemical Co.), poly- 
deoxyinosine (poly dI), or poly-deoxythymidine (poly dT) (Phar- 
macia Inc., Piscataway, NJ). Plates without antigen but treated with 
1% gelatin were used to measure gelatin binding activity. For this, 
test samples were diluted in 1% BSA faction V (Boehringer Mann- 
heim Biochemicals, Indianapolis, IN), or in 0.05% gelatin without 
any detectable difference in plate binding activity. 
To evaluate the ability of anti-idiotype toinhibit antigen binding, 
varying amounts of murine mAb were added to individual wells 
containing SMI IgM~ at a final concentration f 2 #g/ml. After 
a 30-min incubation at room temperature, the samples were as- 
sessed for their ability to bind antigen-coated plates, as described 
above. The binding activities of antibody with inhibitor were com- 
pared with those of serial dilutions of antibody without inhibitor 
to obtain the effective antigen-binding antibody concentrations. 
The percent inhibition of antigen binding was calculated as [1-(effec- 
tive antigen-binding antibody concentration)/(actual concentra- 
tion)] x 100. 
Results 
We generated transfectomas to pair different G6 + IgM H 
chains with the 17.109 + ~ L chain of SMI, a 17.109/G6 +
CLL cell population. For this, we generated ptLTM1, a human 
# chain expression vector (Fig. 1 B). This vector contains 
the functionally rearranged SMI V. I  gene flanked by unique 
restriction enzyme sites, ClaI and SalI, that were introduced 
via site-directed mutagenesis. This vector enabled us to ex- 
change the SMI H chain variable with any one of several 
different functional V.DJ. exons of other G6 + leukemia cells 
or tonsillar lymphocytes. 
From pRTM1, we generated ten additional vector constructs 
that encode highly homologous Ig H chain variable regions 
(Fig. 2). Each variable region is encoded by a rearranged V.1 
gene that shares >99% nucleic acid sequence homology to 
51pl, a V.1 gene expressed uring early fetal development 
(17-19, and unpublished observations). Like SMI, H chain 
constructs SIC, HEN, AND, NEI, BRA, and HUR were 
derived using the rearranged V.1 gene expressed by G6 + 
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Figure 1. Structure ofpSVG-Vk3 and pRTM1 plasmids. (*-) Direc- 
tions of gene transcription; (open labeled boxes) important regions. (a) pSVG- 
Vk3 contains the functionally rearranged Humkv325 Vx gene and C~ exon 
of SMI (17.8 kb) that was inserted into the BamHl site of pSVG-gpt (27, 
28). VK, Humkv325 ofSMI rearranged with J~l; C~, K L chain constant 
region exon; gpt, Ecogpt and SV40 origin of replication: Ori, pBR322 
origin of replication; Amp, ampiciUin resistance g ne. (b) pRTM1 con- 
tains the modified and functionally rearranged V, gene of SMI and Ig 
H chain enhancer (3.4 kb) that was inserted between the EcoRI-HindIII 
sites of pN. x-/~TNP (30), that previously flanked the functionally rear- 
ranged mouse V.TNP gene. VH, the V.1 gene xpressed bySMI that 
is functionally rearranged to J.4, and modified via site-directed mutagen- 
esis to have unique flanking restriction enzyme sites Clal and SalI; E, the 
Ig H chain enhancer region; C/t, exons encoding the human C~ constant 
region; Mem, C~ membrane exon; Neo, the bacterial gene conferring ne- 
omycin resistance, the SV40 origin and SV40 early region; Ori, pBR322 
origin of replication; Amp, ampicillin resistance g ne. 
CLL (8, 18, and unpublished observations). H chain con- 
structs L26, L30, L33, and L42 were derived from the rear- 
ranged V.1 genes expressed by G6 + tonsillar B cells (17). 
From amino acid positions 1-94, L30 shares complete ho- 
mology with SMI (Fig. 2). All other V.1 genes have a GAA 
codon instead of an AAA codon at amino acid position 73, 
resulting in a lysine to glutamine substitution in the third 
framework region (Fig. 2). In addition, BRA has two other 
nonconservative nucleic acid base differences from SMI that 
result in serine to asparagine substitutions atamino acid po- 
sitions 35 and 76. For comparison, the amino acid sequence 
of the H chain variable region of the G6 + IgM, RF 
paraprotein BOR (35) differs from SMI by nine residues 
(Fig. 2). 
In contrast o the relative uniformity in the V. gene- 
encoded protein sequences, the rearranged V. genes differ 
markedly in the CDR3s (Fig. 2). In addition, the lengths 
of the CDR3s vary greatly, ranging from 6-25 codons (L26- 
SIC). Finally, rearranged J. gene segments J,3, J.4, J.5, and 
J,6 are represented in this collection of G6 + H chain vari- 
able regions (Fig. 2). 
To generate transfectomas expressing each of these H chains 
with a 17.109 + L chain, we generated pSVG-VK3. This 
vector contains the genomic DNA of the rearranged K L chain 
gene complex of SMI that encodes a 17.109 + L chain (Fig. 
1 A). Two other G6 + neoplastic B cell populations repre- 
sented in this study, SIC and BRA, also originally expressed 
17.109 + K L chains (15). In addition, the reference IgM, RF 
paraprotein BOR also bears the 17.109 CRI (35). The deduced 
or actual protein sequences ofthese xvariable regions are highly 
homologous, reflecting expression of the conserved V, gene, 
Humkv325, with little or no somatic mutation (Fig. 3) (7, 
15, 16). 
Cotransfection with pSVG-VK3 and the different con- 
structs of pR,TM1 generated transfectomas that each secreted 
intact human IgMK protein. Sample concentrations were de- 
termined via ELISA using monoclonal IgM~ paraproteins, 
ME591 and/or BOR, as standards. The amounts of measured 
IgM~ protein in the supernatants varied between different 
transfectoma cell lines, ranging from a few hundred nano- 
grams to several micrograms of antibody per ml. However, 
the Ig concentration ofeach supernatant assessed using plates 
coated with anti-human/z chain mAb was comparable to 
that determined using plates coated with G6, 17.109, or mAbs 
specific for human K L chains (data not shown). Column chro- 
matography oftransfectoma proteins SMI, HEN, SIC, or L26 
revealed the measured IgM, or Ig x activity to have a mo- 
lecular size similar to that of IgG (data not shown). Collec- 
tively, these results indicate that each transs apparently 
produces intact monomeric IgM, molecules that bear both 
17.109 and G6 CRIs. 
Although each transfectoma secretes intact G6 +/17.109 +
IgM,, only the cell lines generated using the Ig H and L 
chain genes of SMI produced IgM, with significant RF ac- 
tivity. Serial dilutions of concentrated IgM~ from each 
sample were assayed for binding activity to human IgG. The 
IgMK produced by the transfectoma expressing both Ig 
chains of the SMI leukemia cell population (designated SMI) 
has detectable RF activity at concentrations below 1 #g/ml 
(Fig. 4). At any one IgM, concentration, the RF activity 
of SMI is lower than that of the multimeric IgM~ RF 
paraprotein, BOR (Fig. 4). However, except for L30, none 
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CDRI  CDR2 CDR3 JH SEGMENT 
1 20 +- - -+  40 + . . . . . . . . .  60 . . . .  + 80 94+ . . . . . . . . . . . . . . . . . . . . . . . . .  +103 
SMI  Q~QLVQSGAEVKKPGS~VKV~CKASGGTF~SYAISWVRQA~GQG~EWMGGI I~ IFGTANYAQKFQGRVTITADKSTSTAY~LSSLRSEDTAVYYCAR GGNYDYIWGSYRSND AFDIWGQGTMVTVSS JH3 
S IC  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  E . . . . . . . . . . . . . . . . . . . . . . . .  N - YCGGDCY - RWE LLR~DFSED . . . . . .  P . . . . . . . .  JH 3 
MEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  E . . . . . . . . . . . . . . . . . . . . . . . .  PH~SIDDFW - GYYPN YYYYGM-  V . . . . .  T . . . . .  JH6 
AND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  E . . . . . . . . . . . . . . . . . . . . . . . .  VS IFGVVQH YYYYYYM'V .  -K . .T  . . . . .  JH6 
NE I  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  E . . . . . . . . . . . . . . . . . . . . . . . . .  PRLLADVLLWFGELS E ' 'Y  . . . . .  L . . . . .  JH4 
BRA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  E ' 'N  . . . . . . . . . . . . . . . . . . . . .  D- CSGGSCYFW GW' 'P  . . . . .  L . . . . .  J~5 
HUR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  E . . . . . . . . . . . . . . . . . . . . . . . .  VP -PLFFAV GM'V  .. . . .  T . . . . .  JH6 
L26  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  E . . . . . . . . . . . . . . . . . . . . . . . . .  D NW--p  . . . . .  L . . . . .  JH 5 
L30 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  = . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  RTRVSVSTL 'D  "SGYYDFSG YYGM'V  .. . . .  T . . . . .  JH6 
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Figure 2. Sequence comparison of the deduced or actual amino add sequences of G6 + Ig H chain variable regions. (Right) Code name for each 
sequence. The 20-letter amino acid code represents the deduced sequence of SMI. All other sequences are compared with that of SMI. (-) Homology 
between the compared sequences and SMI. Otherwise, letters correspond to the discordant amino acids. Spaces are introduced to maximize sequence 
homology in CDR3. Listed above SMI, amino acid residues are numbered according to Kabat et al. (51). Also listed are labels indicating the first, 
second, and third CDRs, and the region encoded by the J. gene segment. (left) Deduced J. gene segments used to encode the fourth framework of 
the H chain variable regions. At the bottom of the figure is the actual amino acid sequence of BOR. (35) compared to that of SMI. 
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Figure 3. Sequence comparison of the deduced or actual amino acid sequences of 17.109 + Ig L chain variable regions. The amino acid sequences 
are described, and compared to SMI as in Fig. 2 
of the other transfectomas IgM, proteins had any detectable 
ILF activity, even at their highest concentrations (>2/~g/ml 
for all except for AND [0.6/~g/ml]) (Fig. 4). Furthermore, 
although L30 had slight reactivity with human IgG, its RF 
activity only was detectable at concentrations exceeding 
1 #g/ml (Fig. 4). 
The SMI IgM, ILF is isotype specific. SMI has binding 
activity for IgG1 or IgG4 myeloma proteins that is similar 
to that for total human IgG (Fig. 5). In contrast, SMI binds 
poorly to IgG2 and IgG3. The same hierarchy of binding 
activity for IgG1 > IgG4 >> IgG2 > IgG3, is noted using 
either of two sets of purified myeloma proteins representing 
each of the IgG isotypes. As such, the reactivity of the SMI 
IgM, for IgG1 or IgG4 cannot be ascribed to an idiosyn- 
RF Activity vs. IgM Concentration 
AND ~ N, B~A 
HUN 
1 " L33  
L42  
BOR 
o - ~ -  ~.---- = 
1 2 3 4 5 6 
IgM (p.g/ml) 
Figure 4. RF activity of each transfectoma protein compared with BOR. 
Ordinate is OD at 405 nm of the ELISA for RF activity measured on 
plates coated with total human IgG. The abscissa describes the IgM, con- 
centration (/zg/ml) of the assayed sample. Symbols representing titration 
of each sample are indicated. In particular, (O) BOR, (A) SMI, and (D) 
binding activity of L30. 
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cratic binding activity for a particular myeloma protein of 
a single donor. Of note, the BOR IgM~ RF paraprotein also 
reacts primarily with IgG of the IgG1 isotype (data not 
shown). 
In contrast to BOIL and each of the other transfectoma 
proteins, the SMI Ig also has polyspecific antigen binding 
activity. The SMI IgM, reacts strongly with myoglobin, 
actin, or ssDNA, and, by comparison, weakly with thyro- 
globulin (Fig. 6). That the ssDNA binding activity cannot 
be ascribed to trace residual chromatin is demonstrated by 
SMI's reactivity with synthetic polydeoxyinosine (poly dI) 
or polydeoxythymidine (poly dT) (Fig. 6). In every case, the 
binding activity of SMI for each of these antigens is detect- 
able at IgM, concentrations below 1 #g/ml. In contrast, none 
of the other transfectomas IgM, proteins, including L30, 
had detectable binding activity to any of these antigens, even 
IgG Isotype Specificity of SMI 
O ~ IgG1 
~l" 9 IgG2 
a 1 
0 ~' IgG3 
- - - -o - - -  tgG4 
9 IgG (Tota l )  
0 
1 2 3 4 
IgM (p_g/ml) 
Figure 5. IgG isotype specificity of SMI. Graph labeled as in Fig. 4. 
Symbols represent titration of SMI on plates coated with IgG1 (O), IgG2 
(@), IgG3 (A), IgG4 (I-3), or total IgG (11), respectively. 
Polyspecif ic Binding Activity of SMI  
3 
9 myoolobJn 
actin 
2 9 ssDNA tt3 
~ poly dl 
r'~ .L OOfy C~ o 
1 ~ thyroOlobulin 
9 gelatin 
0 
o , ; 
IgM (gg/mt) 
Figure 6. Polyspecific binding activity of SMI. Graph labeled as in Hg. 
4. Symbols represent ti ration of SMI on plates coated with myoglobin 
(o), actin (1"3), single-stranded DNA (Q), poly deoxyinosine (A), poly 
deoxythymidine (A), thyroglobulin (O), or gelatin (11), respectively. 
80 
g 
~ 60 
- 4o 
2O 
Competit ive Inhibition by Anti-CRI 
C-21 
O 
o.o ols ;'o ,is ;0 
Molar Ratio 
F ig~ 8. Inhibition of SMI antigen binding activity by anti-CRl mAb. 
Ordinate lists percent inhibition of SMI binding to myoglobin-coated phtes 
by preincubation of SMI with either 17.109 (@), G6 ([-3), or MOPC-21 
(A), calculated as described in Materials and Methods. The measured values 
are plotted against the molar atio of anti-idiotypic or MOPC-21 inhib- 
itor to SMI IgM,. 
at the highest ested concentration f >2 #g/ml for all ex- 
cept AND (1.6 #g/ml) (data not shown). In addition, the 
IgM, RF, BOP,, also did not have any detectable binding 
activity for any of these antigens, even at concentrations in 
excess of 4/~g/ml. None of the transfectoma proteins, in- 
cluding SMI, had significant binding activity for bovine gelatin 
(data not shown, and Fig. 6). 
We size fractionated the SMI IgM, via FPLC and evalu- 
ated each fraction for antigen binding activity by ELISA. These 
analyses revealed that the predominant IgM actin-binding ac- 
tivity of SMI is similar in size to monomeric IgG (Fig. 7). 
Similarly, the IgM antimyoglobin binding activity of SMI 
also comigrated with human IgG (data not shown). These 
results demonstrate hat the observed polyspecific antigen- 
binding activity of SMI is not dependent on a multimeric 
structure. 
Finally, the polyspecific binding activity of SMI could be 
inhibited specifically by anti-CRI mAbs. Varying amounts 
of IgG murine mAbs were added to individual wells con- 
taining SMI IgM, at a final concentration f 2/~g/ml. After 
a 30-min incubation at room temperature, the samples were 
assessed for their ability to bind myoglobin via ELISA. The 
FPLC of SMI Actin Binding Activity 
0.6 
0.4 ~ ActmBinding 
9 IgM 
0 2 ~  IgG 
0.0o ~ o ~ N 
Fraction 
Figure 7. Size chromatography of SMI antigen binding activity. The 
SMI IgM, was size fractionated via FPLC. Each fraction was assayed for 
human IgM anti-actin activity by ELISA. The ELISA OD at 405 of SM! 
(O) is plotted against the fraction sample number. Also shown are ODs 
at 2,80 nm of the sample fiactions of ME591, a pentameric Waldenstrom's 
!gM, paraprotein (I-I), or monomeric lgG (A). 
percent inhibition of antigen binding were plotted versus the 
molar ratios of murine IgG inhibitor to SMI IgM. We find 
that either 17.109 or G6 can completely inhibit SMI antigen 
binding activity at molar ratios in slight excess of unity (Fig. 
8). In contrast, MOPC-21, a control mouse myeloma IgG1 
protein of unknown specificity, did not inhibit SMI antigen 
binding activity (Fig. 8). 
Discussion 
This study demonstrates hat the random pairing of different 
G6 § Ig H chains with a single 17.109 § ~c L chain generally 
does not produce an IgM autoantibody. Of 11 murine trans- 
fectomas that express IgM~ proteins bearing both the G6 
and 17.109 CRIs, only the native Ig H and L chain pair had 
significant autoantibody activity. This cannot be attributed 
to defective Ig synthesis by the other transfectomas. The cul- 
ture supernatants of each transfectoma were found to have 
stoichiometric concentrations of Ig # chains and K L chains 
by F_LISA. Furthermore, ELISA plates coated with either anti-x 
L chain antibodies or anti-CRI mAbs captured amounts of 
transfectoma IgM that were similar to those of anti-hu-IgM- 
coated plates. Finally, column-chromatography of represen- 
tative samples of the IgM antibodies from those with or 
without RF activity indicated that these proteins have a mo- 
lecular size similar to that of monomeric lgG. Collectively, 
these results indicate that each transfectoma produces intact 
monomeric human IgM~ molecules bearing both 17.109 and 
G6 CRIs. We conclude that the random pairing of different 
G6 + Ig H chains with 17.109" K L chains generally does 
not generate an Ig with antisdf reactivity. 
The H chain constant regions of the transfectoma IgM 
proteins examined in this study are encoded by human Cu 
exons derived from an IgM expression vector, designated 
pN. x-#TNP. In previous tudies, Boulianne t al. noted that 
Sp2/0 cells cotransfected with pN. x-/zTNP and an Ig L chain 
expression vector secreted mostly multimeric lgM (30). How- 
ever, as noted above, we found that most of the IgM secreted 
by each transfectoma comigrates with monomeric human IgG 
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in FPLC. Conceivably, cell culture conditions and/or pro- 
cessing procedures may have influenced the ratio of IgM 
monomers to IgM multimers that is secreted by our trans- 
fectomas (Dr. Marc J. Shulman, personal communication). 
Alternatively, a mutation(s) may have occurred in the human 
Cu exons during the construction of pKTM1, resulting in 
a vector that encodes Ig/x chains that are inefficient in forming 
multimers (36, 37). Restriction mapping studies of pKTM1 
and pN. x-#TNP, however, failed to reveal any differences 
between the two vectors in the regions containing the Ig C~ 
exons (data not shown). In any case, all transfectomas u ed 
in this study possessed the same Ig C, exons, were cultured 
under similar conditions and apparently secreted mostly mono- 
meric IgM. Furthermore, most oflgM autoantibody activity 
of SMI also chromatographically comigrates with human IgG 
(Fig. 7). Therefore, the differences in the binding activities 
of the transfectoma proteins bearing both 17.109 and G6 CRIs 
cannot be ascribed to simple differences in Ig receptor valency. 
The V.1 exon of SMI differs from those of most other 
transfectomas bya single nonconservative base substitution 
at amino acid position 73, resulting in a glutamine to lysine 
substitution (Fig. 2). Although this substitution may be due 
to somatic mutation, this difference also may reflect a genetic 
polymorphism in the V,1 gene encoding the G6-CILI, Pos- 
sibly, the lysine residue at position 73 contributes tothe RF 
binding activity of the SMI transfectoma protein. In this re- 
gard, it should be noted that L30, the only other transfec- 
toma IgM with lysine at amino acid position 73 (Fig. 2), 
also is the only other transfectoma protein that has binding 
activity for IgG that is above background (Fig. 4). It is not 
likely that this substitution enhances the ILF activity of G6- 
reactive IgM proteins, in general, however, as most other G6- 
reactive ILF autoantibodies and CLL Ig do not have a lysine 
at this position (e.g., BOIL, Fig. 2, and references 12, 13, 
35). Another possibility is that the CDR3 of the SMI L chain 
may have been selected for its ability to generate an ILF Ig 
when paired with a G6-reactive H chain that has a lysine 
at this position. Evaluation of the relative contribution of 
this lysine residue to the ILF activity of SMI may require site- 
directed mutagenesis tudies and/or further chain mixing ex- 
periments. 
In any case, the present study delineates the importance 
of the CDR3 to the polyspecifc binding activity of Ig bearing 
these autoantibody-associated CILIs. Each of the G6 + H 
chains has a unique CDR3 sequence. However, except for 
the lysine to glutamine substitution at position 73, the V. 
gene-encoded protein sequences for all but one of the trans- 
fectoma proteins are identical. Moreover, L30 shares com- 
parable homology with SMI in the V. gene-encoded pro- 
tein sequence. Since the pairing of L30 with the 17.109 +
SMI L chain does not produce an Ig with detectable poly- 
specifc autoantibody reactivity, this amino acid substitution 
alone cannot account for the absence of such binding activity 
in the other transfectoma proteins. Collectively, these data 
argue that the somatically generated CDIL3 may contribute 
significantly to the polyspecific autoantibody activity of cer- 
tain G6 + / 17.109 +IgM proteins. 
This indicates that such polyspecific binding activity of 
natural autoantibodies may be a selected specificity. In the 
primary follicles of human fetal spleen, high proportions of 
B cells express autoantibody-associated CRIs, such as G6 and 
17.109 (38). Genetic mechanisms ay favor the frequent rear- 
rangement of Ig V genes that have the capacity to encode 
CILI-bearing IgM autoantibodies (39). However, as with our 
transfectoma studies, the random pairing of such Ig L and 
H chains during ontogeny may infrequently give rise to Ig 
with polyspecific antiself-reactivity. Conceivably, B cells that 
chance xpress functional and self-reactive r ceptors may be 
stimulated to mature into functional B lymphocytes. Such 
selection may contribute to the noted high frequency of B 
cell clones expressing such polyreactive natural autoantibodies 
during early development (40, 41). Indeed, recent data indi- 
cate that most peripheral B cells in mice may be ligand selected 
(42). The selection for self-reactive autoantibody-expressing 
B cells during B cell ontogeny may be similar to that of T 
cells in the thymus, where only the cells expressing receptors 
with low affinity antiself-reactivity areselected for subsequent 
T cell maturation (43-47). 
With regard to CLL, it is not certain whether the apparent 
selection for polyreactive autoreactivity merely reflects its cyto- 
genesis, or if it actually plays a role in leukemogenesis (48, 
49). Recent studies indicate that most patients with CLL 
have leukemia cells that express IgM autoantibodies that, like 
the SMI transfectoma IgM~, react with a variety of different 
self antigens (3-6). The frequency of CLL patients that have 
leukemia B cells that express such polyreactive autoantibodies 
apparently greatly exceeds the noted frequency of polyreac- 
tive B cells in normal embryonic tissues, cord blood or adult 
peripheral blood. Whatever the origin, Guigou et al. (50) 
recently noted that 11-16% of the EBV-transformed Ig- 
secreting B cell clones expressed polyspecific antibodies when 
tested on a panel of nine antigens, including self-antigens. 
Conceivably, B cells selected for expression of slg with au- 
toantibody activity during early B cell ontogeny could be 
stimulated constitutively b self-antigen, thus increasing the 
risk for malignant transformation to CLL. 
Finally, chance somatic mutation in the V genes encoding 
such self-reactive antibodies may enhance the affinity of the 
expressed Ig for self-antigen, contributing toaugmented cell 
stimulation and B cell maturation. Unlike CLL, the neoplastic 
cells in patients with Waldenstrom's macroglobulinemia and/or 
mixed cryoglobulinemia have differentiated into Ig secreting 
cells. The IgM~ KF paraprotein BOK was isolated from the 
plasma of one such patient. It is important o note that 
the Ig H chain of the KF paraprotein BOR differs from the 
deduced amino sequence of 51P1 or SMI by several residues 
(35). Conceivably, these differences are secondary to somatic 
mutations that result in loss of polyspecifc autoreactivity and 
higher affinity for the driving self-antigen(s), possibly human 
IgG. Further comparative studies on the structure-function 
relationships of such IgM autoantibodies may help elucidate 
factors involved in the etiopathogenesis of these lympho- 
proliferative diseases. 
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